Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491852 | 0.84 | L3MBTL1 (0.61) | L3MBTL1HPGDTSHRFKBP1ADPP4 | |
| SCHEMBL6495669 | 0.82 | CHRM3 (0.55) | CHRM3CHRM2OPRM1OPRK1OPRL1 | |
| SCHEMBL5093540 | 0.77 | KMT2A (0.73) | MEN1KMT2AL3MBTL1TSHRDDB1 | |
| SCHEMBL18660281 | 0.72 | MEN1 (0.45) | MEN1KMT2ACHRM3CHRM2 | |
| SCHEMBL25237209 | 0.70 | DPP4 (0.53) | MEN1KMT2AL3MBTL1HPGDTSHR | |
| SCHEMBL15014611 | 0.70 | ACHE (0.56) | KMT2AL3MBTL1HPGDTSHRDPP4 | |
| SCHEMBL28596982 | 0.70 | HPGD (0.53) | MEN1KMT2AL3MBTL1HPGDTSHR | |
| SCHEMBL25231697 | 0.70 | DPP4 (0.53) | MEN1KMT2AL3MBTL1HPGDTSHR | |
| SCHEMBL2223753 | 0.70 | DPP4 (0.53) | MEN1KMT2AL3MBTL1HPGDTSHR | |
| SCHEMBL12384461 | 0.70 | HPGD (0.49) | MEN1KMT2AL3MBTL1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949550-B2 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | MEN1 1315/4885KMT2A 179/4885L3MBTL1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.